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Abstract
Background To investigate the safety and efficacy of a
combined fixed-interval and pro re nata regimen of ranibi-
zumab (FUSION regimen) for treatment of exudative age-
related macular degeneration in patients with good visual
acuity at baseline. To establish whether similar efficacy to
monthly regimens can be achieved with fewer injections,
even in patients with good visual acuity.
Methods This was a prospective, open-label, consecutive
interventional case series in treatment-naïve patients with
exudative age-related macular degeneration. The FUSION
regimen consists of three phases: 1) a loading phase of two
or three injections, depending on presence or absence of
choroidal neovascularization activity at first follow-up, 2)
administration of one injection on disappearance of exuda-
tion, and 3) subsequent administration of two separate injec-
tions at intervals 2 months apart, and then an injection every
3 months. Endpoints included visual acuity, presence of
fluid, adverse events and number of injections administered.
Results Seventeen eyes of 17 Caucasian patients were in-
cluded. Mean patient age was 76 years, and 15 patients were
female. Mean baseline visual acuity was 67.5 letters (median
67), with Snellen equivalent 20/50++, ranged between 45 (20/
125) and 83 (20/20−−). At 3 months, mean change in best-
corrected visual acuity (BCVA) was +2.3 letters (median +9)
compared with baseline (p00.3). At 6 months, mean change
in BCVAwas +4.2 letters (median +9) comparedwith baseline
(p00.02). At 12 months, one patient had discontinued the
study.Mean change in BCVAwas 5.6 (median +10) compared
with baseline (p00.04). No patient lost ≥15 letters, and 14
patients (87.5%) lost <5 letters. The mean number of injec-
tions was 6.9. One patient experienced a retinal pigment
epithelium tear; no other complications were observed.
Conclusions The FUSION regimen for ranibizumab has the
potential to maintain visual gains achieved during the load-
ing phase, as reported in studies with monthly injections,
even in eyes with a relatively good visual acuity at baseline.
These 12-month results warrant validation in a larger, ran-
domized controlled trial.
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Introduction
The approval of ranibizumab (Novartis Pharma AG) marked
a significant change in treatment outcomes for exudative
age-related macular degeneration (AMD), and established
a new standard of care for the treatment of this disabling
disease. Although monthly injections of ranibizumab
resulted in the highest efficacy [1], concerns were raised
regarding potential ocular and systemic safety risks, and
feasibility and costs.
Alternative regimens attempting to achieve similar effi-
cacy with fewer injections of ranibizumab have been ex-
plored. In the PIER [2] and EXCITE studies [3, 4] mean
best-corrected visual acuity (BCVA) improved after three
initial monthly injections; however, this declined during the
subsequent fixed-quarterly injection phase (Fig. 1).
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Trials investigating pro re nata (PRN) regimens [5–9]
also showed loss of mean BCVA from the peak value
reached after monthly initiation phase. Furthermore, PRN
regimens all rely on monthly follow-up, which is not usually
achieved in the ‘real-world’ setting. Furthermore, PRN regi-
mens with retreatment only administered when lesion activ-
ity recurs (i.e., a visual acuity [VA] loss of ≥5 letters) might
be associated with a risk of irreversible visual loss that is
significant [10].
In the recently reported CATT study, PRN ranibizumab
barely achieved non-inferiority to monthly treatment with
24.9 % vs 34.2 % of these groups respectively, gaining >15
letters (p00.09) [11]. PRN ranibizumab led to less reduction
of retinal thickness and a numerically lower functional gain
compared with monthly treatments. Moreover, at week 36, the
plotted mean changes in VA for the PRN arms start to diverge
downhill in comparison with the monthly arms, suggesting
that, after 12months, the differences in benefit might increase.
Regimens such as ‘inject and extend’ or ‘treat and ex-
tend’, in which the intervals between re-injections are pro-
gressively extended if there is no fluid, appear to be more
favourable than with PRN regimens [12–16]. However,
these regimens carry the risk of long-term unnoticed disease
recurrence, and require understanding of the algorithm by
both patient and practitioner to manage frequent changes to
the visit schedule.
The rationale for the ‘FUSION’ regimen that combines
fixed injections after defined periods of (apparent) inactivity
with the PRN approach has been reported [17]. The FU-
SION regimen will be practical enough to be broadly imple-
mented into clinical routine.
Here we present a small proof-of-concept study, designed
to explore the efficacy of the FUSION regimen. The main
objective is to ascertain if this FUSION regimen will be
effective enough in the current incident population presenting
in clinical practice who have higher baseline BCVA than
patients in most previous trials.
Materials and methods
This was a prospective, open-label, consecutive inter-
ventional case series of a 12-month study of patients with
exudative AMD treated with intravitreal injections of 0.5 mg
ranibizumab in a combined fixed-interval and PRN regimen.
The 12-month results reported in this work include only
patients enrolled during November and December 2010.
Ranibizumab (LUCENTIS®; Novartis Farmacéutica SA,
Spain) is approved by the European Medicines Agency and
the US Food and Drug Administration, and is the current
standard of care for treatment of exudative AMD.
The study adhered to the tenets of the Declaration of
Helsinki. The protocol was approved by an Ethics Commit-
tee, and informed consent was obtained from all patients.
All patients were given an explanation of the trial, and
information about possible risks and discomforts by the
investigator. Patients who provided written informed con-
sent and met all eligibility criteria were enrolled into the
study. All participants were scheduled to be followed up
monthly; in cases where the choroidal neovascularization
(CNV) had been inactive for 6 months, follow-up visits
were held at 1.5-month intervals.
General inclusion and exclusion criteria
Patients included in the study were of either gender, were
aged ≥50 years, provided written informed consent, and
were capable of complying with all study and follow-up
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Fig. 1 Summary of mean
BCVA change from baseline
over time in patients treated with
ranibizumab. Clinical trial
results shown were achieved
with various ranibizumab treat-
ment regimens [17]. (Repro-
duced with permission from
Ophthalmologica)
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Patients were excluded from the study if they: had a
history or evidence of severe cardiac disease; had experi-
enced a stroke within the 6 months preceding trial entry; had
undergone any major surgical procedure within 1 month
of study entry or any treatment with an investigational
agent in the 60 days prior to the beginning of the study;
or had known serious allergies to the fluorescein dye
used in angiography (mild allergy amenable to treatment
was permitted), or to the components of the ranibizumab
formulation.
Ophthalmic inclusion and exclusion criteria
The following inclusion criteria were applied to the study
eye: (1) subfoveal or juxtafoveal CNV owing to AMD,
defined by fluorescein angiography (FA), (2) presence on
optical coherence tomography (OCT) of subretinal or intra-
retinal fluid associated or not with macular oedema, (3)
BCVA in the study eye between 20/20 and 20/125, inclu-
sive, (4) total area of the lesion (including blood, neovascu-
larization and scar/atrophy) of ≤8 disc areas, of which at
least 50% must be active CNV (defined as the neovascular
component of the lesion as defined by FA; all angiographic
subtypes [predominantly classic, minimally classic and oc-
cult] were eligible), (5) clear ocular media and adequate
pupillary dilatation to allow collection of fundus photo-
graphs and FA of a sufficient quality to be analysed; intra-
ocular pressure of 21 mmHg or less, and (6) no previous
treatment for AMD.
Ophthalmic exclusion criteria comprised: (1) presence of
scarring or atrophy >75% of the total lesion size (patients
with subfoveal scar or atrophy were excluded), (2) subreti-
nal haemorrhage >75% of the total lesion size, (3) presence
of serous retinal pigment epithelial detachments >5 disc
areas, (4) presence of intraocular inflammation (≥ trace cell
or flare), epiretinal membrane, macular hole or vitreous
haemorrhage, (5) history of idiopathic or autoimmune-
associated uveitis in either eye, (6) significant media opac-
ities, including cataract, which might interfere with VA,
assessment of toxicity, or fundus photography in the study
eye, (7) presence of other causes of CNV, including patho-
logical myopia (spherical equivalent of −3 diopters or more,
or axial length of 25 mm or more, or fundus findings
suggestive of pathologic myopia), ocular histoplasmosis
syndrome, angioid streaks, choroidal rupture and multifo-
cal choroiditis, (8) any retinal treatment (aside from anti-
oxidants), including (but not limited to) intravitreal
injections, photodynamic therapy with verteporfin, laser
photocoagulation, or surgery, (9) history of rhegmatoge-
nous retinal detachment, pars plana vitrectomy or corneal
transplant, and (10) previous radiation in the region of
the study eye.
Study protocol and assessments
Consenting patients were screened for the study with a
medical and ophthalmological history, measurement of
BCVA, slit-lamp examination, measurement of intraocular
pressure, and funduscopic examination with pharmacologi-
cal pupil mydriasis (one drop phenylephrine 10% plus tro-
picamide 1%). In addition, colour fundus photographs were
obtained with non-stereoscopic 35° photography of field 2
(Topcon TRC 50DX IA®, Topcon Corporation, Tokyo,
Japan), and FA (Spectralis HRA + OCT®, Heidelberg En-
gineering, Heidelberg, Germany) and spectral-domain OCT
(SD OCT; Spectralis HRA + OCT®, Heidelberg Engineer-
ing) were carried out. Safety evaluations, measurement of
BCVA, eye examinations, and OCT scans were conducted at
all study visits. FA was performed at least at baseline,
months 1 and 3, and at those visits where injections were
not predetermined.
Regimen (FUSION) and administration of intravitreal
drug
The FUSION regimen consists of three steps. First, a load-
ing phase of three consecutive monthly injections is given.
If CNV activity is resolved at the first follow-up visit, the
loading phase can be reduced to two monthly injections.
Second, a PRN regimen is established on demand, and
intravitreal injections are given if CNV activity is present,
defined by fluorescein leakage at FA and/or the presence of
abnormal intraretinal or subretinal fluid assessed by OCT,
until cessation of activity. After cessation of CNV activity,
patients still receive one injection. Third, after cessation of
CNVactivity, patients receive fixed injections every 2 months
for two courses, and every 3 months for two courses.
At the intermediate visits, between the preplanned fixed
injections, patients are treated according to PRN criteria.
The PRN intermediate visits are held at 4-weekly intervals
during the first two periods of fixed injections every
2 months, and at 6-weekly intervals when fixed injections
are given every 3 months. Treatment is restarted at the first
sign of CNV lesion activity (as defined in the Ophthalmic
inclusion and exclusion criteria section) at the intermediate
visits. The retreatment cycle is restarted in cases of signifi-
cance relapse during the period of fixed injections, until
cessation of CNV activity. If a patient never shows resolu-
tion of fluid, injections according to PRN criteria would be
given at every visit (Fig. 2).
Intravitreal therapy was carried out in sterile conditions
after topical anaesthesia, and the injection site was cleaned
with 5 % povidone iodine. Lid speculum was located, and
additional topical anaesthesia and povidone iodine were
administered immediately prior to injection. Ranibizumab
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(0.5 mg/0.05 ml) was injected through the pars plana at
4 mm of limbus into the vitreous cavity. Patients were
instructed to consult the study team if they experienced
decreased vision, eye pain, unusual redness or any new
symptoms.
Safety and efficacy endpoints
All adverse events were registered. Ophthalmic variables,
such as intraocular pressure, general ophthalmic examination,
colour fundus photography, and OCT, were observed at each
follow-up visit. FAwas carried out at least at month 3 and at
those visits where fixed injections were not predetermined.
The primary outcome measure was the change in BCVA
between baseline and months 3, 6, and 12. Secondary
vision-related outcome measures were the percentage of
patients with gain of ≥5, >10, and ≥15 letters ETDRS at
12months. The percentage of patients losing <5, <15, and <30
letters at 12 months was also observed. In addition, the fol-
lowing endpoints were also considered: the mean and median
VA at 6 and 12 months, and the mean number of injections at
12 months.
Statistical analysis
Descriptive statistics included age, gender and baseline
BCVA. Median BCVA change was assessed using the Wil-
coxon test. The total number of intravitreal injections was
also considered, as was the frequency with which treatment
was required at the PRN visits that was not anticipated by
the FUSION schedule at the predetermined fixed treatment
visits. Owing to the high percentage of patients with VA >20/
40, statistical analysis was also carried out by subgroup of
percentages of patients who maintained VA, lost ≥3 lines of
VA or gained ≥3 lines of VA, including the group of patients
with basal BCVA ≥20/40 and the group of patients with basal
BCVA <20/40.
All adverse events occurring up to 12 months after
the first injection were included. Stata IC (version 11.1;
Stata Corp, College Station, TX, USA) was used for
statistical analysis. A p value <0.05 was considered sta-
tistically significant.
Results
The study included 17 eyes of 17 treatment-naïve Caucasian
patients (15 female) with a mean age of 76 years (range 61
to 87 years). The right eye was treated in four cases
(23.5 %). Mean baseline BCVA was 67.5 letters (median
67, Snellen equivalent 20/50++, range 45 letters [20/125] to
83 letters [20/20−−]). Approximately 50% of the patients
had a VA >73 letters (20/40 Snellen) with a mean VA of 82
letters (20/25++).
At 3 months, the mean change in VAwas +2.3 letters (p0
0.3) from baseline (median +9 letters). At 6 months, the
mean change in VAwas +4.2 letters (p00.02) from baseline
(median +9 letters). At 12 months, the mean change in VA
was +5.6 letters (p00.04) from baseline (median +10 letters).
Mean BCVA at 6 and 12 months were 71.7 and 73.1 letters
(corresponding to 20/40++ and 20/32−− respectively).Median
BCVA at 6 and 12 months were 76.5 and 77.5 letters
(corresponding to 20/32++ and 20/25−− respectively).
All 17 patients were followed-up until 6 months. At
12 months, one patient had discontinued the study. Out of
a total of 170 permissible visits, 155 were performed
(91.2 %). No patient lost ≥15 letters, and vision was main-
tained in 14 patients (87.5 %), defined as loss <5 letters.
Vision was maintained in seven out of eight patients
(87.5 %) with VA at baseline <20/40, and in seven out of
eight patients (87.5 %) with baseline VA ≥20/40. At
12 months, nine of the 16 patients (56.3 %) gained ≥5
letters: seven of the eight patients (87.5 %) with baseline
VA <20/40, and two of the eight patients (25.0 %) with a
baseline VA ≥20/40. Two of the 16 patients (12.5 %) expe-
rienced an improvement in VA of ≥15 letters: two out of the
eight patients (25 %) with a baseline VA <20/40. Six of the
16 patients gained >10 letters (37.5 %): six of the eight
patients (75.0 %) with baseline VA <20/40.
The mean number of injections at month 12 was 6.9 out
of 12 possible (median 7, ranging from 5 to 10). Eleven
patients (64.7%) required the three loading injections; six
patients had inactive CNV (resolution of fluid) after one
injection and thus received only one more injection in the
loading phase, i.e., the third injection was postponed by
1 month, initiating the fixed bimonthly injections. PRN
retreatment outside the fixed schedule had to be performed
Active lesion Inactive lesion Injection
Month
0 1 2 3 4 5 6 7 8 9 10 11 12
Fig. 2 The FUSION regimen: patients are treated by a combination of
PRN and fixed-dose injections according to lesion activity. Five exam-
ples of the FUSION regimen are represented in the figure [17]. (Repro-
duced with permission from Ophthalmologica)
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in three of the 16 patients (18.8 %). In 29 of the 69 (42.0 %)
who were administered fixed injections, the lesion did not
present active exudation at OCT and/or FA.
One patient (5.9 %) in the overall study population expe-
rienced a retinal pigment epithelium tear after the first intra-
vitreal injection. No other adverse events were observed.
Discussion
The objective of this pilot study was to explore the safety
and efficacy of the FUSION regimen, which presents an
alternative to monthly injections, in a population of patients
with a high BCVA score, and therefore at a high risk of
vision loss. This high-baseline BCVA is consistent with the
BCVA of patients at initial presentation in clinical practice, a
scenario that has not been addressed in previous trials. If this
regimen could show benefit even in this particular popula-
tion, further research with larger clinical trials would be
recommended.
At 6 months, an interim analysis showed no safety sig-
nals that would prohibit continuation of the study. In terms
of efficacy, the following trend was discovered: BCVA
gains after the loading dose could be maintained from
1 month after the loading dose to month 6. This trend may
suggest superiority compared with regimens that apply PRN
criteria (i.e., retreatment is triggered by recurrent disease
activity), because most reports describing PRN regimens
show BCVA loss from the values obtained after the loading
dose. Therefore, the study was continued to month 12.
Mean change in VA at 12 months using the FUSION
regimen was a gain of 5.6 letters, despite the relatively good
baseline VA, and is within the range of VA gain shown by
other trials including patients with a higher mean VA at
baseline. After administration of ranibizumab according to
the FUSION regimen, no patient experienced severe or
moderate visual loss (loss of ≥30 or ≥15 letters, respective-
ly). Fourteen patients (87.5 %) did not experience any
significant loss of vision, defined as loss of <5 letters. It is
noteworthy that this level of maintaining vision was also
achieved for the subgroup of patients with VA ≥20/40. In
addition, 56.3 % of patients had gain of vision of ≥5
letters; 25.0 % of those patients with VA of ≥20/40 also
had gain of ≥5 letters. Owing to the good level of VA at
baseline, it was anticipated that significant VA gain of
three lines or more would be less frequent than in other
trials with much lower VA at baseline. Two of the 16
patients (12.5 %) gained three lines of VA. Both of these
patients had VA <20/40 at baseline, representing 25.0 %
of this subgroup. Six of the 16 patients (37.5%) gained >10
letters: 75.0 % of those patients with VA <20/40. The propor-
tion of patients with ≥15 letter gain (12.5 %) may appear
smaller in comparison to those in the MARINA [18] and
ANCHOR [19] studies. This could be explained by the fact
that the patients described here had a baseline BCVA of 67.5
letters, and half of the patients had a VA >73 letters (20/40
Snellen) with ameanVA of 82 letters (20/25++). This baseline
VA is in the order of 10–20 letters higher than the baseline VA
in other trials (Table 1, Figs. 3 and 4). Patients with high
baseline VA are less likely to gain BCVA and are at risk of
higher BCVA loss [20, 21].
The mean number of injections (6.9 out of 12 possi-
ble) is within the value that could be expected for PRN
regimens. The pre-planned schedule of fixed injections was
Table 1 Main characteristics of different trials and clinical series.
Mean baseline visual acuity for the FUSION regimen was 10–20 letters
higher than in other studies. Despite this higher level of baseline mean
visual acuity, patients showed a mean gain of 2.3 letters at month 3, 4.2
letters at month 6, and 5.6 letters at month 12. There was no loss


















ANCHOR [19] 140 Monthly 47 10.0 10.6 11.3 0.6 1.3 12.0
MARINA [18] 240 Monthly 53 5.9 6.5 7.2 0.6 1.3 12.0
EXCITE [4] 118 3 + quarterly 58 6.0 5.2 2.8 −0.8 −3.2 5.5
PIER [2] 61 3 + quarterly 54 4.5 2.0 −0.2 −2.5 −4.7 6.0
PrONTO [5] 40 3 + PRN (5 letter / 100 μm / fluid) 56 10.8 12.0 9.3 1.2 −1.5 5.6
SUSTAIN [23] 513 3 + PRN (5 letter / 100 μm / fluid) 56 5.8 4.0 3.6 −1.8 −2.2 5.6
Biswas [24] 27 3 + PRN (5 letter / 100 μm) 58 5.8 5.7 3.2 −0.1 −2.6 5.6
Dadgostar [8] 124 1 + PRN (OCT, clinical) 47 7.0 8.0 5.0 1.0 −2.0 5.2
FUSION 17 2–3 + fixed bi- or 3­monthly +
PRN (OCT, FA)
67 2.3 4.2 5.6 1.9 3.3 6.9
Δ3M VA, change in mean visual acuity at 3 months; Δ6M VA, change in visual acuity at 6 months; Δ12M VA, change in visual acuity at
12 months; Diff. Δ6–Δ3M, difference in mean visual acuity from month 3 to month 6; Diff. Δ12–Δ3M, difference in visual acuity from month 3
to month 12; FA, fluorescein angiography; OCT, optical coherence tomography; PRN, pro re nata; VA, visual acuity
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appropriate for the majority of patients, with few patients
requiring additional injections. However, 18.8 % of patients
who had resolution of fluid required injection at those visits
where treatment had not been predetermined by a fixed ad-
ministration. These patients would have been missed by the
‘treat and extend’ regimens, where these intermediate visits
between injections do not take place. Furthermore, the timings
of the fixed injections do not appear to be exaggerated, be-
cause approximately half of the patients presented with some
exudation at those visits.
Perhaps an indication of the success of the FUSION regi-
men in the population of patients with a higher risk of losing
vision is the fact that 42 % of the fixed injections were
performed in inactive lesions. This might suggest that the
regimen anticipates the relapse of neovascular exudation.
These data indicate that the FUSION regimen, with its
fixed injections, sufficiently stabilizes the disease in most
patients, but has the flexibility to counteract acute and
unexpected disease recurrence via the PRN injections
(Fig. 2). Therefore, the FUSION regimen is flexible enough
to spare injections in patients who have a more favourable
response to treatment and also allows, at the other extreme
of the spectrum, monthly treatments if needed (Fig. 2).
Compared with PRN regimens, treatment before the recur-
rence of CNV activity appears to lower the risk of losing
vision or losing the vision that is gained initially.
Several FA evaluations were performed during the FU-
SION study; however, the availability of SD OCT has
greatly reduced the number of angiographies performed in
clinical practice and could potentially mean that, in the
future, angiography as an invasive technique will be no
longer considered as necessary in the follow-up of patients
with exudative AMD. At present, there is no consensus on
this matter; thus, the use of FA in addition to SD OCT is
based on clinical judgement of the retinal specialists, and
varies between centres and countries. Although this question
was not specifically addressed in the FUSION study, in our
practice, FA is very useful in providing an entire picture of
the lesion, particularly in cases of questionable OCT find-
ings in chronic lesions, or specially in juxtafoveal lesions
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Fig. 3 Change in visual acuity from month 3 to month 6 and from
month 3 to month 12 in the different trials. Only MARINA, ANCHOR,
PrONTO, Dadgostar and FUSION showed a positive change frommonth
3 to month 6. Only MARINA, ANCHOR and FUSION showed a
positive change frommonth 3 to month 12, despite the mean visual acuity









































Fig. 4 Mean change from
baseline in visual acuity
observed in the different
studies. Despite the high level
of visual acuity at baseline in
the FUSION series, mean
visual acuity gain is obtained
at 3, 6, and 12 months
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The duration of this study was only 12 months, whereas
PrONTO [5], ANCHOR [19] and MARINA [18] showed
that there was a benefit in treating for 2 years. Thus, the
FUSION regimen, if validated, should be followed for at
least 2 years. The HORIZON trial [22] (using a PRN regi-
men) has shown that continued treatment is needed in a
large proportion of patients in the third and fourth year,
and that less frequent dosing in years 3 and 4 was associated
with visual decline. Therefore, a PRN regimen is likely to be
insufficient even after 2 years.
Although conceptually different, the FUSION regimen
has some similarities with the proposed ‘treat and extend’
regimen [12–16], because both regimens aim to prevent
disease recurrence. The main differences between the FU-
SION and ‘treat and extend’ regimens are that, in the latter,
the periods between treatments are extended in a continuous
linear form, and there are no visits in between these periods.
Long extension, however, bears an increased risk of unno-
ticed disease reactivation. In at least 18 % of the patients in
this study, the ‘treat and extend’ regimen would have missed
early detection of relapse of exudation. The goal of the
FUSION regimen is to treat before relapse of neovascular
activity, ideally in an inactive lesion.
The lack of a control group and the small sample size are
the main limitations of this study; however, these are limi-
tations inherent in pilot studies.
The purpose of this exploratory 12-month study was not
to establish a recommendation for using the FUSION regi-
men, but to provide sufficient evidence to justify and raise a
proposal for a larger, randomized controlled trial. This trial
would aim to establish the exact role of the FUSION ap-
proach, and to validate if it can be used as an alternative to
monthly regimens without compromising the extent of vi-
sion gain, even in the current population of patients in daily
clinical practice who may present with very good levels of
vision.
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